share_log

Canaccord Genuity Maintains Buy on Pulmonx, Lowers Price Target to $15

Benzinga ·  May 2 15:16

Canaccord Genuity analyst Jon Young maintains Pulmonx (NASDAQ:LUNG) with a Buy and lowers the price target from $16 to $15.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment